Publications: Miss Kimberley Allen Philbey

Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S et al. ( 2023 ) . Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis . Therapeutic Advances in Neurological Disorders vol. 16 ,

Salavisa M, Mohamed B, Allen-Philbey K, Stennett AM, Campion T, Schmierer K ( 2023 ) . Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis . Neurology Clinical Practice vol. 13 , ( 6 )

Schmierer K, Baker D, Nawaz T, Allen-Philbey K, Barkhof F, Chataway J, Hooper R, Mihaylova B et al. ( 2022 ) . 153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS) . Journal of Neurology Neurosurgery & Psychiatry . vol. 93 ,

K A-P, A S, T B, AC J, A M, S G, R D, G G et al. ( 2022 ) . Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 65 ,

Topcu G, Smith L, Mhizha-Murira JR, Goulden N, Hoare Z, Drummond A, Fitzsimmons D, Evangelou N et al. ( 2022 ) . Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial . Pilot and Feasibility Studies vol. 8 , ( 1 )

Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al. ( 2021 ) . Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients . Therapeutic Advances in Neurological Disorders vol. 14 ,

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study . Multiple Sclerosis and Related Disorders vol. 57 ,

Kuri A, Jacobs BM, Leddy S, Schmierer K, Turner B, Allen-Philbey K, Stennett A, Giovannoni G et al. ( 2021 ) . Evaluation of remote assessments for multiple sclerosis in an in-home setting . Multiple Sclerosis and Related Disorders vol. 54 ,

Dobson R, ALLEN-PHILBEY K, Giovannoni G, Baker D, Schmierer K ( 2021 ) . Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis . Multiple Sclerosis and Related Disorders

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up . NEUROLOGY . vol. 96 ,

Allen-Philbey K, Middleton R, Tuite-Dalton K, Baker E, Stennett A, Albor C, Schmierer K ( 2020 ) . Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement? . Frontiers in Neurology vol. 11 ,

Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al. ( 2020 ) . Severe skin reactions associated with cladribine in people with multiple sclerosis . Multiple Sclerosis and Related Disorders . vol. 43 ,

Reyes S, Suarez S, Allen‐Philbey K, Thomson A, Giovannoni G ( 2020 ) . The impact of social capital on patients with multiple sclerosis . Acta Neurologica Scandinavica vol. 142 , ( 1 ) 58 - 65 .

Reyes S, Suarez S, Allen-Philbey K, Yildiz Ö, Mathews J, Anjorin G, Edwards F, Jain C et al. ( 2020 ) . Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 41 ,

Christmas T, Reyes S, Singh N, Allen-Philbey K, Giovannoni G ( 2020 ) . Postprandial Somnolence in People with Multiple Sclerosis . NEUROLOGY . vol. 94 ,

Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2019 ) . 192 Does socioeconomic status impact on the prescription of disease-modifying treatments in people with multiple sclerosis? . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,

Allen-Philbey K, Silveira F, Turner B, Giovannoni G, Schmierer K ( 2019 ) . 212 Is there an ethnicity bias of access to MS services? The barts health experience revisited . Journal of Neurology Neurosurgery & Psychiatry . vol. 90 ,

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. ( 2019 ) . Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients . NEUROLOGY . vol. 92 ,

Reyes S, Suarez S, Allen-Philbey K, Thomson A, Giovannoni G ( 2019 ) . The Impact of Social Capital on Patients with Multiple Sclerosis . NEUROLOGY . vol. 92 ,

Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies . Multiple Sclerosis and Related Disorders vol. 27 , 247 - 253 .

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine . Multiple Sclerosis and Related Disorders vol. 24 , 20 - 27 .

Mao Z, Alvarez-Gonzalez C, Yildiz O, Allen-Philbey K, Turner B, Gnananpavan S, Marta M, Mathews J et al. ( 2018 ) . Personalised dosing of cladribine for people with multiple sclerosis (P3.400) . Neurology . vol. 90 ,

Reyes S, Allen-Philbey K, Suarez S, Yildiz Ö, Turner B, Gnanapavan S, Schmierer K, Marta M et al. ( 2018 ) . The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. (P2.346) . Neurology . vol. 90 ,

Allen-Philbey K, Albor C, Raciborska D, Turner B, Giovannoni G, Schmierer K ( 2017 ) . PO109 Is there an ethnicity bias of access to multiple services in the nhs? – the barts health experience . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,

Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Gnanapavan S, Marta M, Baker D et al. ( 2017 ) . PO134 Personalised dosing of cladribine to treat multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,